ALN-ANG3 / Alnylam, Regeneron - LARVOL DELTA

ANCHOR-POC: Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease (clinicaltrials.gov) - P2 | N=270 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2027 ➔ Apr 2028 | Trial primary completion date: Jun 2027 ➔ Sep 2027

Enrollment open • Trial completion date • Trial primary completion date • Diabetic Nephropathy • Nephrology • Renal Disease • APOB

ANCHOR-POC: Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease (clinicaltrials.gov) - P2 | N=270 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P2 trial • Diabetic Nephropathy • Nephrology • Renal Disease • APOB

A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Trial primary completion date: Sep 2025 ➔ Dec 2026 | Active, not recruiting ➔ Recruiting | N=42 ➔ 88 | Trial completion date: Sep 2025 ➔ Dec 2026

Enrollment change • Enrollment open • First-in-human • Trial completion date • Trial primary completion date • Dyslipidemia